• General Dermatology
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management

FDA Clears Sofwave to Improve Appearance of Cellulite


The non-invasive treatment has no downtime for patients.

SofwaveTM now offers patients a US Food and Drug Administration (FDA) cleared treatment to reduce the appearance of cellulite by targeting and thickening the dermal layer1. The procedure relies on a novel delivery method of ultrasound technology called synchronous ultrasound parallel beam technology (SUPERBTM) to stimulate collagen formation. The treatment is safe for all skin types and colors.

A single 30–45-minute session was previously known for softening wrinkles and supporting lax skin around a patient’s eyebrows, skin, and neck. The new FDA clearance means Sofwave is clinically proven to reduce the appearance of cellulite to give patients more tout skin on the thighs and buttocks.

A clinical study of Sofwave provided 2 treatments spaced out 2-4 weeks apart on the upper thighs and buttocks of study participants (N=68). Photographs taken at baseline and the 3-month post-procedure mark were assessed by blinded independent reviewers to identify and grade pre-treatment and post-treatment images. Reviewers correctly identified the post-treatment images for nearly 90% of study participants. Improvement was also evaluated using the Global Aesthetic Improvement scale (GAIS) and Laxity Scale (LS). No serious or unanticipated adverse effects were reported during the study.

The global cellulite treatment market in 2021 was valued at more than $1 billion and expected to grow at a compound annual growth rate of 11% through 20302.


Sofwave treatment comparison photos

1. Eckhouse DS, Scafuri L. Sofwave medical announces FDA clearance of SUPERB™ Technology for cellulite. Sofwave. https://sofwave.com/news/sofwave-medical-announces-fda-clearance-of-superb-technology-for-cellulite/. Published January 9, 2023.Accessed January 12, 2023.

2. Grandview Research. Cellulite treatment market size & share report, 2022-2030. Cellulite Treatment Market Size & Share Report, 2022-2030. https://www.grandviewresearch.com/industry-analysis/cellulite-treatment-market. Published August 9, 2022. Accessed January 12, 2023.

Related Videos
Video 2 - featuring 2 panelists in, "Empowering Patients: Understanding New Treatments and Long-Term Considerations with Fresh Approaches and FDA Endorsements  "
Video 2 - 1 KOL featured in, "Adolescent Acne Management: Strategic Approaches and Leveraging Clascoterone Cream "
Video 1 - 1 KOL featured in, "Comprehensive Acne Management: Exploring the Role of Combination and Food Independent Treatments in an Adolescent Treatment-Naïve Patient "
Lawrence Eichenfield, MD, an expert on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, experts on atopic dermatitis
Video 3 - featuring 2 panelists in, "Navigating Treatment Challenges: Addressing Negative Responses and Determining the Next Course of Action "
© 2024 MJH Life Sciences

All rights reserved.